US FDA orders classwide REMS for long-acting opioids
This article was originally published in Scrip
Executive Summary
The US FDAis requiring 16 manufacturers of 24 branded and generic opioid medicines to jointly develop a classwide risk evaluation and mitigation strategy (REMS) to reduce deaths and serious injuries resulting from misuse, abuse and overdose.